Nail penetration of sertaconazole with a sertaconazole-containing nail patch formulation

American Journal of Clinical Dermatology

Volumn 7, Issue 4, 2006, Pages 259-262

  Susilo, Rudy ^a   Korting, Hans C ^b   Greb, Wolfgang ^c   Strauss, Uwe Phillip ^a,d  

^a Research and Development   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c FOCUS Clinical Drug Development GmbH   (Germany)

^d Arzneimittel GmbH and Co KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; SERTACONAZOLE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG PENETRATION; DRUG TISSUE LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; MINIMUM INHIBITORY CONCENTRATION; NAIL; NAIL DYSTROPHY; NORMAL HUMAN; ONYCHOMYCOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THUMB;

ADMINISTRATION, TOPICAL; ADULT; ANTIFUNGAL AGENTS; FEMALE; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; NAILS; THIOPHENES;

EID: 33747169865     PISSN: 11750561     EISSN: 11750561     Source Type: Journal    
DOI: 10.2165/00128071-200607040-00007     Document Type: Article

References (17)

1. Sais G, Jucgla J, Peyri J. Prevalence of dermatophyte onychomycosis in Spain: a cross-sectional study. Br J Dermatol 1995; 132: 758-61
2. Heikkila H, Stubb S. The prevalence of onychomycosis in Finland. Br J Dermatol 1995; 133: 699-703
3. Elewski BE, Charif MA. Prevalence of onychomycosis in patients attending a dermatology clinic in north western Ohio for other conditions. Arch Dermatol 1997; 133: 1172-3
4. Summerbell RC, Kane J, Krajden S. Onychomycosis, tinea pedis and tinea manum caused by nondermatophyte filamentous fungi. Mycoses 1989; 32: 609-19
5. Palacin C, Sacristan A, Ortiz JA. In vitro activity of sertaconazole. Arzneim-Forsch/Drug Res 1992; 42: 699-705
6. Agut J, Palacin C, Sacristyn A, et al. Inhibition of ergosterol synthesis by sertaconazole in Candida albicans. Arzneim-Forsch/Drug Res 1992; 42: 718-20
7. Guitèrez EQ. Phase III multicentre study to evaluate the efficacy and safety of 2% sertaconazole cream in comparison with 2% miconazole cream in patients affected by fungal infections of the skin. J Eur Acad Dermatol Venereol 1993; 2 Suppl. 2: 82-6
8. Pedragosa P. Therapeutic efficacy of the new antimycotic sertaconazole in the treatment of cutaneous dermatophytosis. Arzneim-Forsch/Drug Res 1992; 42: 689-74
9. US Department of Health and Human Services, Food and Drug Administration. International Conference on Harmonisation; good clinical practice: consolidated guideline; notice of availability. Federal Register 1997 May 9; 62 (90): 25691-709
10. Establishment and validation of a bioanalytical method for the validation of sertaconazole in human nail. Neuss, Germany: FOCUS Clinical Drug Development GmbH, 1999 (Data on file)
11. Establishment and validation of a bioanalytical method for the determination of sertaconazole in human plasma. Neuss, Germany: FOCUS Clinical Drug Development GmbH, 1999 (Data on file)
12. Carrillo-Munoz AJ, Guglietta A, Palacin C, et al. In vitro antifungal activity of sertaconazole compared with nine other drugs against 250 clinical isolates of dermatophytes and Scopulariopsis brevicaulis. Chemotherapy 2004; 50: 308-13
13. Drouhet E, Dupont B. In vitro antifungal activity of sertaconazole. Arzneim-Forsch/Drug Res 1992; 42: 705-10
14. Kronauer C, Gfesser M, Ring J, et al. Transonychial water loss in healthy and diseased nails. Acta Dermatol Venereol 2001; 81: 175-7
15. Hollmann J, Melnik BC, Lee MS, et al. Stratum corneum and nail lipids in patients with atopic dermatitis: decrease in ceramides - a pathogenetic factor in atopic xerosis? [in German] Hautarzt 1991; 42: 302-6
16. Zaun H. Brittle nails: objective assessment and therapy follow-up [in German]. Hautarzt 1997; 48: 455-61
17. Ständer H, Ständer M, Nolting S. Incidence of fungal involvement in nail psoriasis [in German]. Hautarzt 2001; 52: 418-22